Valeant Pharmaceuticals International, Inc. 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Feb 22, 2016
Insider Transaction Report
Form 4
Schiller Howard Bradley
EVP and CFO
Transactions
- Tax Payment
Common Stock, no par value
2016-02-18$91.45/sh−2,245$205,305→ 388,630 total - Tax Payment
Common Stock, no par value
2016-02-18$91.45/sh−51,846$4,741,317→ 336,784 total
Footnotes (4)
- [F1]Represents the amount of shares withheld by the registrant to cover certain tax obligations due upon vesting of Matching Restricted Share Units.
- [F2]This number includes the maximum number of Common Shares that may be delivered in settlement of performance-based Restricted Share Units ("PSUs") that were previously reported on Form 4 in Table II, giving effect to the cancellation of such PSUs in respect of a potential 200,000 Common Shares. See note (3).
- [F3]The initial grant of PSUs was reported to vest based on total shareholder return ("TSR") between a price of $136.41 starting on December 1, 2014 and the average stock price for the 20 trading days starting on each measurement dates: 25% would vest on September 1, 2017, 50% on December 1, 2017 and 25% on March 1, 2018, (or 25% on September 1, 2018, 50% on December 1, 2018 and 25% on March 1, 2019, if applicable). Unit vesting is contingent on TSR performance between 10% and 30% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels.
- [F4]Represents the amount of shares withheld to cover certain tax obligations due upon vesting of Performance Restricted Share Units.